GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
-
Two poster presentations detailing preclinical studies conducted at
MD Anderson Cancer Center will highlight data demonstrating the potential of the Company’s dual antagonist of CXCR4 and E-selectin
“The data to be presented at ASH provide further support for targeting both CXCR4 and E-selectin as a novel treatment strategy for patients with AML, particularly patients with FLT-3 ITD mutations. Both posters detail preclinical studies conducted at the
Details on
1. Poster# 1171
Title: FLT3 Inhibitors Upregulate CXCR4 and E-selectin Ligands and CD44 Via ERK Suppression in AML Cells, and Blockade of CXCR4 and E-selectin Signaling with GMI-1359 Overcomes AML Resistance to Quizartinib In Vitro and In Vivo.
Authors:
Session
Date/Time:
2. Poster# 3348
Title: Co-targeting E-selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-leukemia Therapy.
Authors: K.-
Session
Date /Time:
The accepted abstracts are available online through the ASH meeting website.
About GMI-1359
GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4 — both adhesion molecules involved in tumor trafficking and metastatic spread. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow such as AML and multiple myeloma or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer, as well as in osteosarcoma, a rare pediatric tumor. GMI-1359 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma, a rare cancer affecting about 900 adolescents a year in
About
Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development and commercialization of the Company’s product candidates, as well as the presentation of data from preclinical studies and clinical trials, and the potential benefits and impact of the Company’s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005721/en/
Investor Contact:
Phone: 650-888-0902
Email: sannes@annesassociates.com
Media Contact:
Phone: 410-299-3310
Email: jamielacey@presscommpr.com
Source: